Process Validation in Support of Manufacture of a Bacterial Toxin
Download Your Copy
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
The Health Protection Agency's Process & Analytical Development Group (PADG) has completed studies for an international Biopharm company to support validation of a bacterial toxin manufacturing process. The product is a therapeutic form of a botulinum toxin and was originally developed and manufactured in HPA’s GMP manufacturing facilities at Porton Down. The validation studies were on the downstream processing stages of the process using scaled down models.